Richard W. Paul & Associates LLC Reduces Holdings in Zoetis Inc. (NYSE:ZTS)

Richard W. Paul & Associates LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,055 shares of the company’s stock after selling 233 shares during the period. Richard W. Paul & Associates LLC’s holdings in Zoetis were worth $1,195,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Fairfield Bush & CO. purchased a new stake in Zoetis during the 1st quarter worth about $134,000. Sequoia Financial Advisors LLC lifted its holdings in Zoetis by 5.3% during the 1st quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock worth $786,000 after purchasing an additional 211 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in Zoetis by 3.9% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock worth $9,727,000 after purchasing an additional 1,914 shares in the last quarter. Covestor Ltd lifted its holdings in Zoetis by 102.8% during the 1st quarter. Covestor Ltd now owns 724 shares of the company’s stock worth $137,000 after purchasing an additional 367 shares in the last quarter. Finally, Merit Financial Group LLC raised its holdings in shares of Zoetis by 92.8% in the 1st quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock valued at $442,000 after acquiring an additional 1,127 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZTS. Piper Sandler raised their price target on Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, February 20th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Stifel Nicolaus reduced their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Finally, The Goldman Sachs Group increased their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $222.11.

View Our Latest Analysis on ZTS

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now owns 20,417 shares in the company, valued at $4,037,257.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 2,209 shares of company stock worth $408,453 in the last quarter. 0.15% of the stock is owned by company insiders.

Zoetis Trading Down 0.6 %

Shares of ZTS stock traded down $0.95 during trading hours on Wednesday, reaching $164.06. The company’s stock had a trading volume of 997,827 shares, compared to its average volume of 2,692,865. The stock has a market capitalization of $75.03 billion, a P/E ratio of 32.54, a P/E/G ratio of 2.55 and a beta of 0.85. Zoetis Inc. has a one year low of $151.03 and a one year high of $201.92. The firm’s fifty day simple moving average is $184.16 and its 200 day simple moving average is $181.77. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.15 earnings per share. Equities research analysts expect that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is presently 34.12%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.